Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...

Gilead pharmaceutical company announced today (Tuesday, Feb. 18) that the U.S. Food and Drug Administration has accepted the company’s  “new drug applications” for lencapavir, a twice-yearly ...

Arcus Biosciences (RCUS) stock falls as Gilead (GILD) decides not to buy rights to its anticancer drug casdatifan. Read more ...

The US Food and Drug Administration (FDA) has accepted Gilead’s new drug application (NDA) for lenacapavir and set a prescription drug user fee act (PDUFA) target action date of ...

Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...

Arcus Biosciences presented new Phase 1/1b data for a kidney cancer program over the weekend and picked a dose to move ...

Shares of Gilead Sciences Inc. advanced 7.46% to $103.31 Wednesday, on what proved to be an all-around poor trading session ...

Gilead Sciences (GILD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...